Press Release Friday 22 June 2018
The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.
Sativa Investments PLC
(“Sativa” or “the Company”)
Sativa passes resolution at General Meeting to broaden investment policyto meet widening global demand for medicinal cannabis
Sativa Investments PLC (NEX:SATI), the UK’s only medicinal cannabis investment vehicle, announces that all Resolutions were passed by the requisite majority at the Company’s General Meeting today, including Resolutions to broaden its investment strategy beyond Canada, the authority to allot shares, and the disapplication of pre-emption rights.
Since listing on the NEX Exchange Growth Market on Thursday 29th March 2018, Sativa has pursued numerous potential investments and has already announced that it has completed two investments, these being in Veritas Pharma Inc. and Rapid Dose Therapeutics Inc. on 21 May and 23 May respectively. This week, the Company appointed pharmacologist Sir Alasdair Breckenridge, to its already heavyweight Advisory Board, to assist Sativa in navigating its way in the sector and advise on investments ahead of anticipated regulatory change in Europe, including the UK.
Geremy Thomas, founder and Chief Executive Officer of Sativa Investments, said: “Since Sativa’s listing, the market has had a governmental and societal sea change of attitudes to medicinal cannabis. In the past two weeks, the UK has seen the two high profile cases of Alfie Dingley and Billy Caldwell, two young boys who suffer from rare forms of epilepsy and need medicinal cannabis for their treatment, which was initially rejected to them by the UK authorities, generating widespread consternation and condemnation. In both cases, the Home Secretary then intervened and issued a licence from the Home Office.
“It is hard to see how the UK’s stance and that of a few other leading EU countries, which are also resisting medicinal advanced therapy, can continue without accepting that the controlled use of medicinal cannabis has an important part to play in healthcare.”
The Directors of the Company accept responsibility for the contents of this announcement.
– Ends –
For further information please contact:
Founder & Chief Executive Officer
Sativa Investments PLC
+44 (0) 20 7971 1255
NEX Exchange Corporate Adviser
Peterhouse Corporate Finance Limited
+44 (0) 20 7469 0930
Financial PR and IR
Julian Bosdet / Dylan Mark /Alejandra Campuzano
+44 (0) 20 7469 4630
Notes to Editors
Sativa will look for well-placed opportunities within the dynamic regulatory environment of the Medicinal Cannabis sector and the Company’s investment strategy will focus on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily accepted, with an initial focus on Canada. The Company has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment.
The Company’s equity interest in a proposed investment may range from a minority position, to a controlling interest, or to 100 per cent ownership. The ventures that Sativa intends to acquire can either be public or private.
The Company’s Board and Medical Cannabis Advisory Board have a combined 60 years’ industry experience with strong and extensive contacts in the industry, with significant pharmaceutical strength and experience. Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development.
For more information on Sativa Investments, please visit: